Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 EXPANDING CLINICAL EXPERIENCE AND SAFETY PROFILE OF ZIFTOMENIB SUPPORT ITS EVALUATION IN COMBINATION WITH APPROVEDFLT3 INHIBITORS IN FRONTLINE AML 

KURA ONCOLOGY AND KYOWA KIRIN LAUNCH CLINICAL TRIAL EVALUATING DUAL INHIBITION OF NPM1 AND FLT3 MUTATIONS IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)

 KOMET-017-IC TRIAL OF INTENSIVE CHEMOTHERAPY COMBINATION WILL ASSESS MRD NEGATIVE CR AND EFS AS DUAL-PRIMARY ENDPOINTS TO SUPPORT POTENTIAL U.S. ACCELERATED AND FULL APPROVAL 

KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE FIRST PATIENT DOSED IN PIVOTAL PHASE 3 KOMET-017 TRIAL OF ZIFTOMENIB FOR FRONTLINE ACUTE MYELOID LEUKEMIA (AML)

 KOMET-001 IN R/R NPM1-M AML MET ITS PRIMARY ENDPOINT WITH ZIFTOMENIB MONOTHERAPY DEMONSTRATING SIGNIFICANT CLINICAL BENEFIT AND DEEP RESPONSES 

KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE PUBLICATION OF PIVOTAL ZIFTOMENIB DATA IN RELAPSED/REFRACTORY NPM1-MUTATEDAML IN THE JOURNAL OF CLINICAL ONCOLOGY

SAN DIEGO, SEPT. 24, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT MANAGEMENT IS SCHEDULED TO PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCE.

KURA ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCE

ANALYST/INVESTOR EVENT SHOWCASES OPPORTUNITIES FOR KO-2806 (DARLIFARNIB) IN COMBINATION WITH PI3K INHIBITORS, KRAS INHIBITORS AND ANTIANGIOGENIC TYROSINE KINASE INHIBITORS (TKIS)

KURA ONCOLOGY HIGHLIGHTS PRECLINICAL DATA DEMONSTRATING POTENTIAL OF FARNESYL TRANSFERASE INHIBITORS TO OVERCOME DRUG RESISTANCE IN COMBINATION WITH KEY TARGETED THERAPIES ACROSS MULTIPLE TUMOR TYPES

SAN DIEGO, SEPT. 05, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (THE COMPANY) (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT ON SEPTEMBER 2, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NONSTATUTORY STOCK OPTIONS TO PURCHASE 82,950 SHARES OF COMMON STOCK TO SEVEN (7) NEW EMPLOYEES UNDER THE COMPANY'S 2023 INDUCEMENT OPTION PLAN, AS AMENDED. THE COMPENSATION COMMITTEE APPROVED THE STOCK OPTIONS AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SEPTEMBER 16 EVENT TO HIGHLIGHT PRECLINICAL DATA ON THE COMBINATION OF FTI AGENTS WITH MULTIPLE CLASSES OF TARGETED THERAPIES

KURA ONCOLOGY TO HOST VIRTUAL INVESTOR AND ANALYST EVENTS ON FARNESYL TRANSFERASE INHIBITOR PROGRAM

SAN DIEGO, AUG. 28, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT MANAGEMENT IS SCHEDULED TO PARTICIPATE IN THREE INVESTOR CONFERENCES IN SEPTEMBER.

KURA ONCOLOGY TO PARTICIPATE IN THREE UPCOMING INVESTOR CONFERENCES

 FDA PRIORITY REVIEW OF NEW DRUG APPLICATION (NDA) FOR ZIFTOMENIB IN ADULTS WITH R/R NPM1-M AML WITH PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE SET FOR NOVEMBER 30, 2025   FULLY ENGAGED IN COMMERCIAL READINESS ACTIVITIES IN ALIGNMENT WITH REGULATORY REVIEW TIMELINE   KOMET-017-IC (INTENSIVE CHEMOTHERAPY) AND NIC (NON-INTENSIVE CHEMOTHERAPY) PHASE 3 STUDIES IN NEWLY DIAGNOSED AML ON TRACK TO START IN 2H 2025   THREE CLINICAL ABSTRACTS FROM KURA'S FARNESYL TRANSFERASE INHIBITORS (FTI) DEVELOPMENT PROGRAM ACCEPTED FOR PRESENTATION AT THE 2025 ESMO CONGRESS   $630.7 MILLION IN PRO FORMA CASH, TOGETHER WITH ANTICIPATED COLLABORATION AGREEMENT PAYMENTS, EXPECTED TO SUPPORT ZIFTOMENIB COMMERCIALIZATION THROUGH THE FRONTLINE AML COMBINATION SETTING   MANAGEMENT TO HOST WEBCAST AND CONFERENCE CALL TODAY AT 4:30 P.M. ET  SAN DIEGO, AUG. 07, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY REPORTED SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDED A CORPORATE UPDATE.

KURA ONCOLOGY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

SAN DIEGO, AUG. 04, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (THE COMPANY) (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT ON AUGUST 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NONSTATUTORY STOCK OPTIONS TO PURCHASE 646,700 SHARES OF COMMON STOCK TO THIRTY-FIVE (35) NEW EMPLOYEES UNDER THE COMPANY'S 2023 INDUCEMENT OPTION PLAN, AS AMENDED. THE COMPENSATION COMMITTEE APPROVED THE STOCK OPTIONS AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN DIEGO, JULY 31, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED IT WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS AFTER THE CLOSE OF U.S. FINANCIAL MARKETS ON THURSDAY, AUGUST 7, 2025. KURA'S MANAGEMENT WILL HOST A WEBCAST AND CONFERENCE CALL AT 4:30 P.M. ET / 1:30 P.M. PT TO DISCUSS THE FINANCIAL RESULTS AND PROVIDE A CORPORATE UPDATE.

KURA ONCOLOGY TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS

SAN DIEGO, JULY 03, 2025 (GLOBE NEWSWIRE) -- KURA ONCOLOGY, INC. (THE COMPANY) (NASDAQ: KURA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY COMMITTED TO REALIZING THE PROMISE OF PRECISION MEDICINES FOR THE TREATMENT OF CANCER, TODAY ANNOUNCED THAT ON JULY 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NONSTATUTORY STOCK OPTIONS TO PURCHASE 141,750 SHARES OF COMMON STOCK TO EIGHT (8) NEW EMPLOYEES UNDER THE COMPANY'S 2023 INDUCEMENT OPTION PLAN, AS AMENDED. THE COMPENSATION COMMITTEE APPROVED THE STOCK OPTIONS AS AN INDUCEMENT MATERIAL TO SUCH EMPLOYEES' EMPLOYMENT IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

Kura Oncology, Inc.

KURA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Kura Oncology, Inc.

KURA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

KURA